Differentiation-inducing activity of hydroxycamptothecin on cancer stem-like cells derived from hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 56, Issue 8, 2011, Pages 2473-2481

  Zhang, Yi ^a   Song, Wen Jie ^a   Zhang, Fu Qin ^a   Liu, Wei Hui ^a   Dou, Ke Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; Differentiation; Hepatocellular carcinoma; Hydroxycamptothecin; Side population

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; HEPATOCYTE NUCLEAR FACTOR 4; HYDROXYCAMPTOTHECIN; MICRORNA; MICRORNA 122; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; CELL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; FLOW CYTOMETRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ALBUMINS; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL LINE, TUMOR; FLOW CYTOMETRY; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASTIC STEM CELLS; SIDE-POPULATION CELLS;

EID: 79960934727     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1601-6     Document Type: Article

References (38)

1. Dawe RS. Hepatocellular carcinoma. Lancet. 2004;363:899.
2. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614-616.
3. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253-1261. (Pubitemid 44427449)
4. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells - old concepts, new insights. Cell Death Differ. 2008;15:947-958. (Pubitemid 351712600)
5. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542-2556. (Pubitemid 46890873)
6. Hussain SZ, Strom SC, Kirby MR, et al. Side population cells derived from adult human liver generate hepatocyte-like cells in vitro. Dig Dis Sci. 2005;50:1755-1763. (Pubitemid 41413886)
7. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827-4833. (Pubitemid 46910191)
8. Harris MA, Yang H, Low BE, et al. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res. 2008;68:10051-10059.
9. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240-251. (Pubitemid 44049156)
10. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol. 2003;3:338-343. (Pubitemid 36908936)
11. Lin TL, Vala MS, Barber JP, et al. Induction of acute lymphocytic leukemia differentiation by maintenance therapy. Leukemia. 2007;21:1915-1920. (Pubitemid 47299964)
12. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-apl). Leukemia. 2000;14:491-496. (Pubitemid 30142878)
13. Kawamata H, Tachibana M, Fujimori T, Imai Y. Differentiation-inducing therapy for solid tumors. Curr Pharm Des. 2006;12:379-385.
14. Kondo K, Tsuneizumi K, Watanabe T, Oishi M. Induction of in vitro differentiation of mouse embryonal carcinoma (f9) cells by inhibitors of topoisomerases. Cancer Res. 1991;51:5398-5404.
15. Jing Y, Hashimoto S, Nakajo S, Nakaya K. Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia hl-60 cells. Leuk Res. 1994;18:299-304. (Pubitemid 24123537)
16. Santos A, Calvet L, Terrier-Lacombe MJ, et al. In vivo treatment with cpt-11 leads to differentiation of neuroblastoma xenografts and topoisomerase i alterations. Cancer Res. 2004;64:3223-3229.
17. Kamiya A, Gonzalez FJ, Nakauchi H. Identification and differentiation of hepatic stem cells during liver development. Front Biosci. 2006;11:1302-1310. (Pubitemid 43253423)
18. van der Zee AG, de Jong S, Keith WN, et al. Quantitative and qualitative aspects of topoisomerase i and ii alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 1994;54:749-755. (Pubitemid 24068332)
19. Boonsong A, Curran S, McKay JA, et al. Topoisomerase i protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol. 2002;33:1114-1119.
20. Gouveris P, Lazaris AC, Papathomas TG, et al. Topoisomerase i protein expression in primary colorectal cancer and recurrences after 5-fu-based adjuvant chemotherapy. J Cancer Res Clin Oncol. 2007;133:1011-1015. (Pubitemid 47561716)
21. Ling YH, Tseng MT, Nelson JA. Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a DNA topoisomerase i inhibitor. Differentiation. 1991;46:135-141.
22. Zhang XW, Jiang JF, Xu B. Differentiation-inducing action of 10- hydroxycamptothecin on human hepatoma hep g2 cells. Acta Pharmacol Sin. 2000;21:364-368. (Pubitemid 30220147)
23. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101:14228-14233.
24. Wu C, Wei Q, Utomo V, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007;67:8216-8222. (Pubitemid 47395158)
25. Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol. 2010;20:85-92.
26. Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol. 2010;42:31-38.
27. Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem. 2009;108:1031-1038.
28. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-284. (Pubitemid 40488633)
29. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas abcg2+ and abcg2- cancer cells are similarly tumorigenic. Cancer Res. 2005;65:6207-6219. (Pubitemid 40994406)
30. Hu C, Li H, Li J, et al. Analysis of abcg2 expression and side population identifies intrinsic drug efflux in the hcc cell line mhcc-97l and its modulation by akt signaling. Carcinogenesis. 2008;29:2289-2297.
31. Polgar O, Robey RW, Bates SE. Abcg2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol. 2008;4:1-15.
32. Chen Z, Liu F, Ren Q, et al. Suppression of abcg2 inhibits cancer cell proliferation. Int J Cancer. 2010;126:841-851.
33. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31:1035-1042. (Pubitemid 36975674)
34. Jones EA, Clement-Jones M, James OF, Wilson DI. Differences between human and mouse alpha-fetoprotein expression during early development. J Anat. 2001;198:555-559. (Pubitemid 32519980)
35. Li J, Ning G, Duncan SA. Mammalian hepatocyte differentiation requires the transcription factor hnf-4alpha. Genes Dev. 2000;14:464-474. (Pubitemid 30131891)
36. Herbst RS, Nielsch U, Sladek F, et al. Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells. New Biol. 1991;3:289-296.
37. Bai S, Nasser MW, Wang B, et al. Microrna-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem. 2009;284:32015-32027.
38. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of mir-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526-3536.